Drug Search Results
More Filters [+]

Fulranumab

Alternative Names: fulranumab, jnj-42160443, jnj-42160443, jnj42160443, jnj 42160443
Latest Update: 2023-08-20
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: NGF Binder

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Fulranumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Osteoarthritis|Osteoarthritis, Knee|Osteoarthritis, Hip

Phase 2: Mononeuropathies|Neuralgia, Postherpetic|Low Back Pain|Peripheral Nervous System Diseases|Cancer Pain|Arthralgia|Osteoarthritis, Hip|Osteoarthritis, Knee|Chronic Pain|Cystitis, Interstitial|Urinary Bladder Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2014-003224-40

P3

Terminated

Osteoarthritis, Knee|Osteoarthritis, Hip

2017-02-11

CR100070

P3

Completed

Osteoarthritis

2016-10-10

CR106249

P3

Completed

Osteoarthritis

2016-09-19

2013-001830-16

P3

Completed

Osteoarthritis, Hip|Osteoarthritis, Knee

2016-09-19

Recent News Events